Evidence map›Paper›PMID 36298518›Full record

ArticleVaccines2022

A Vaccine with Multiple Receptor-Binding Domain Subunit Mutations Induces Broad-Spectrum Immune Response against SARS-CoV-2 Variants of Concern.

Xu-Chen Hou, Hui-Fang Xu, Yang Liu, Peng Sun, Lin-Wei Ding, Jun-Jie Yue, Tian-Tian Wang, Xin Gong, Jun Wu, Bo Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xu-Chen HouDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Hui-Fang XuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Yang LiuSchool of Mechatronical Engineering, Beijing Institute of Technology, Beijing 100081, China.
Peng SunDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Lin-Wei DingDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Jun-Jie YueDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.ORCID 0000-0002-2549-9261
Tian-Tian WangDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Xin GongDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Jun WuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Bo LiuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Beijing Institute of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the emergence of more variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the immune evasion of these variants from existing vaccines, the development of broad-spectrum vaccines is urgently needed. In this study, we designed a novel SARS-CoV-2 receptor-binding domain (RBD) subunit (RBD5m) by integrating five important mutations from SARS-CoV-2 variants of concern (VOCs). The neutralization activities of antibodies induced by the RBD5m candidate vaccine are more balanced and effective for neutralizing different SARS-CoV-2 VOCs in comparison with those induced by the SARS-CoV-2 prototype strain RBD. Our results suggest that the RBD5m vaccine is a good broad-spectrum vaccine candidate able to prevent disease from several different SARS-CoV-2 VOCs.

Indexed as

RBDSARS-CoV-2subunit vaccineVOCsyeast

Identifiers

PMID36298518
PMCPMC9609383
OpenAlexW4304190073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.